NDATOPICALGEL
Approved
Mar 1997
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
3/8 — Basic
Drug data last refreshed Yesterday · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
CONDYLOX (podofilox) is a topical gel small molecule indicated for the treatment of external genital warts (condyloma acuminata). It works as a cytotoxic agent that arrests mitosis in metaphase, causing necrosis of wart tissue. Patients self-apply the product directly to affected areas.
$0.017BPart D
LOE ApproachingDeclining
Minimal commercial momentum with very low Part D utilization suggests a contracted team focused on maintenance rather than growth initiatives.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
CONDYLOX currently has zero linked job openings, reflecting its LOE status and minimal commercial priority within AbbVie's portfolio. Career opportunities are limited to maintenance-mode roles with modest compensation growth potential.
Brand ManagerField Sales Representative
Worked on CONDYLOX at AbbVie? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.